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1 ERK5 Expression in Human Prostate Cancer  
Abstract:  
The MEK5/ERK5 pathway has recently been implicated in prostate and breast 
carcinogenesis. Over-expression of MEK5 is associated with aggressive prostate cancer. 
In this study, we examined the role of ERK5 (a MAPK and specific substrate for MEK5) 
in prostate cancer. ERK5 immunoreactivity is significantly upregulated in prostate cancer 
(PC) (n=81) when compared to BPH (n=20) (P<0.0001). Increased levels of ERK5 
cytoplasmic signals correlates closely with Gleason sum score (P<0.0001), bony 
metastases (P=0.0044), and locally advanced disease at diagnosis (P=0.0023), with a 
weak association with shorter disease-specific survival (P=0.036). A subgroup of 15 (of 
81) patients showed strong nuclear ERK5 localisation, which correlates with poor 
disease-specific survival and, on multi-variant analysis, was an independent prognostic 
factor (P<0.0001). Analysis of ERK5 expression in matched tumour pairs (before and 
after hormone relapse, n=26) revealed that the presence of ERK5 nuclear expression is 
significantly associated with hormone insensitive disease (P=0.0078), a trend not seen for 
ERK5 cytoplasmic expression. Similarly, ERK5 protein expression was found to be 
increased in the androgen independent LNCaP-DCC cell line. We obtained the following 
in vitro evidence to support the above expressional data: (i) ERK5 overexpressing PC3 
cells have enhanced proliferative capability (P<0.0001); (ii) the MEK1 inhibitor, 
PD184352, blocking ERK1/2 activation at low dose, did not suppress proliferation but did 
significantly decrease proliferation at a higher dose required to inhibit ERK5 activation; 
(iii) overexpression of ERK5 upregulated MMP-1, -2 and -9 promotor activity; (iv) co-
transfection of ERK5wt and MEK5D constructs in PC3 cells results in predominant 
ERK5 nuclear localisation, similar to that observed in aggressive clinical disease. Taken 
together, our results establish the importance of ERK5 in aggressive prostate cancer.  
Keywords: Prostate Cancer; ERK5; MEK5  
2 ERK5 Expression in Human Prostate Cancer  
Introduction  
Prostate cancer is the most commonly diagnosed cancer and the second commonest cause 
of cancer related death in men in the western world [1]. Prostate cancer is usually 
androgen dependent and the majority will regress upon treatment with androgen ablation. 
Unfortunately, about 20% of patients do not show favourable response, and even among 
the responders, there is an overall risk of 80% to develop relapsed cancer at a median 
period of 24 months with hormone manipulation. Therefore, better prognostic markers 
will facilitate stratification of patients to different treatment protocols aimed at improving 
survival outcome.  
The clinical picture in the advanced stages of prostate cancer is dominated by the problem 
of bony metastases, which occur in 85% of patients. They represent the most important 
cause of morbidity, causing pain and complications such as pathological fractures and 
spinal cord compression. The development of bone metastases in patients with advanced 
prostate cancer occurs at a constant rate of approximately 8% per year, reaching 40% at 5 
years. There is a remarkable affinity between prostate cancer cells and bone, the 
predominant site of metastasis, which is frequently osteoblastic in nature.  
The family of mitogen-activated protein kinases (MAPKs) plays an essential role in the 
transduction of extracellular signals to cytoplasmic and nuclear effectors. MAP kinase 
kinases (MEKs/MAPKKs) represent protein kinases upstream of MAP kinases (MAPKs), 
critically controlling cellular proliferation and apoptosis. Mitogen/extracellular signal 
regulated kinase kinase-5 (MEK5) is the most recently identified MAPKK and 
specifically activates ERK5, also known as Big MAP kinase 1 (BMK1) [2, 3]. The  
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ability of inhibitors of the classical MAPK (ERK1/2) cascade to block ERK5 activation 
suggested that ERK5 might regulate some cellular functions originally attributed to 
ERK1/2. The MEK5/ERK5 pathway is potently activated by EGF and is required for 
EGF induced proliferation [4] and connexin 43 gap junction communication [5]. ERK5 is 
almost twice the size of the other MAPKs (815 amino acids). Its unique COOH-terminal 
tail contains a myocyte enhancer factor 2 (MEF2)-interacting domain and a potent 
transcriptional activation domain [6]. The activity of several transcriptional factors have 
been shown to be regulated by ERK5, including MEF2, c-Fos and Fra-1, Sap-1, c-Myc 
and NF-κB [7-11]. It plays key role in embryogenesis: ERK5 knock-out embryos die 
between day 9.5 and 11.5 due to severe cardiovascular defects [12, 13] whereas mice 
lacking ERK1 develop normally [14, 15]. Interestingly, a recent study has shown that 
MEK5 knock-out mice also die, at approximately embryonic day 10.5 [16].  
We have previously shown that abnormal MEK5/ERK5 signalling is important in prostate 
cancer [17]. Strong MEK5 expression correlates with aggressive disease. Activation of 
MEK5 induced signalling induced proliferation (p<0.0001), motility (p=0.0001) and 
invasion in LNCaP prostate cancer cells (p<0.0001). In this study, we further explore the 
role of ERK5, the specific substrate for MEK5, in prostate cancer.  
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Materials and methods  
Human prostate tissue samples  
For immunohistochemical studies of ERK5 expression, Ethics Committee approval and 
the consent of patients with cancer of the prostate (CaP) and benign prostatic hypertrophy 
(BPH), undergoing transurethral prostatectomy (TURP), were obtained. Diagnosis was 
confirmed by histopathological examination. Specimens containing greater than 75% 
tumour involvement were selected for analysis. The primary immunohistochemical 
analysis included 81 patients with prostate cancer, median age 73 years (range 55 – 90) 
and median Gleason sum score 8 (range 5 – 10). Twenty cases of BPH specimens were 
studied as controls. Formalin-fixed and paraffin waxed-embedded specimens were 
obtained at the time of diagnosis, following TURP, prior to any anti-androgen therapy. 
The secondary immunohistochemical analysis included 26 patients (52 matched tumours), 
all of which had received conventional androgen deprivation therapy (orchidectomy, 
antiandrogens or androgen ablation therapy). Patients were selected for treatment if they 
initially responded to treatment (response was defined by prostate-specific antigen (PSA) 
levels falling by at least 50%), but subsequently relapsed. Patients were classed as having 
hormone escaped cancer when sustained rising PSA levels were noted and were selected 
for study if a post-hormone relapse sample was available [18].  
Immunohistochemical analysis  
Polyclonal anti-ERK5, raised in sheep as previously described [19] and polyclonal anti-
MEK5 (Stressgen, USA) were optimised for immunohistochemical analysis (data not  
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shown). Archive paraffin wax-embedded serial sections (4µm) taken from clinical 
prostate samples were prepared and incubated with the desired antibody overnight at 4°C 
and immunohistochemical analysis was performed as described previously [20]. The 
staining was developed with diaminobenzidine tetrahydrochoride (DAB; Sigma, UK), 
with haematoxylin used as a counterstain. Heart muscle was used as a positive control; no 
primary antibody as a negative control. The slides were assessed by two independent 
observers (MM and SMcC) with inter-observer agreement on the grading system 
confirmed in the first 20 cases. Both observers were blinded to the clinical details for 
these cases prior to evaluation. The cytoplasmic immunoreactivity signals were correlated 
with ERK5 expression and scored as either absent (0), weak (1), moderate (2), or strong 
(3) as previously published [21, 22]. Nuclear immunoreactivity signals were scored as 
either positive or negative.  
Cells and Cell Culture  
The PC-3 cell line (passage 27) was purchased from the European Collection of Animal 
Cell Cultures (ECACC, Salisbury, UK) and was maintained in growth medium [RPMI 
1640 (Gibco BRL, Invitrogen, Paisley, UK), containing HEPES buffer (25mM) and L-
Glutamine (20mM)], supplemented with 10% heat-inactivated fetal calf serum (Sigma-
Aldrich, Dorset, U.K.), 100units/ml of penicillin, and 100µg/ml of streptomycin (Gibco 
BRL); this was referred to as full medium. Androgen-independent LNCaP (LNCaP-DCC) 
cells were derived in-house by Prof. Craig Robson from LNCaP cells, following 
continuous passaging in an environment depleted of androgens for a period of over 9 
months. The LNCaP-DCC cell line did not require androgen to proliferate, however the  
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cells were still responsive to androgen stimulation. Passage number matched parental 
LNCaP cells were also maintained.  
Plasmids and generation of stable clones  
The EGFP-C1 ERK5 and pCMV HA-ERK5wild type(wt) plasmids were provided by Prof. 
P Cohen. A constitutively active mutant of MEK5 (MEK5D-HA) was obtained from Dr 
JD Lee (Department of Immunology, The Scripps Research Institute, USA) and inducible 
293 cells expressing MEK5D was generated as previously described [17]. PC3 cells 
overexpressing ERK5 were generated by transfection with EGFP-ERK5 using 
Superfect® Transfection Reagent (Qiagen, Crawley, UK) according to the manufacturer’s 
recommendations. Following selection with geneticin (G418, 1mg/ml; Sigma), colonies 
were left to form for 2-3 weeks. Control stable cell lines were similarly established with 
the vector (EGFP-C1) alone. Individual colonies were sub-cultured and screened for 
ERK5 expression by Western analysis. Presence and subcellular localisation of ERK5 
was also confirmed by fluorescent microscopy.  
Fluorescent Microscopy  
PC3 cells were plated on sterile coverslips placed in 6-well culture dishes and cultured in 
the desired condition for 48 hours. Cells were washed in PBS, fixed with methanol for 20 
minutes at -20ºC and allowed to air dry. The coverslips were mounted on microscope 
slides using an anti-photobleaching solution, Vectashield (Vector Laboratories, 
Peterborough, UK), which contains the nuclear stain Diamino-2-phenylinodole (DAPI). 
The slides were then viewed using a Leica DMR/HCS microscope (100x magnification;  
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Leica Microsystems Ltd., Milton Keynes, UK). Photographs were taken with a SPOT 
digital camera and software (version 3.5.2 for Windows; Diagnostic Instruments Inc., 
Michigan, USA).  
MMP promoter studies  
At 48 h prior to transfection, 2x10
4 
PC3 cells were seeded per well in a 48-well plate. 
MMP-1 (-3803), MMP-2 (-1659) and MMP-9 (-670) constructs containing 5’- flanking 
fragments upstream to the transcription initiation start site linked to a luciferase reporter 
gene (MMP-luc) were co-transfected with pCMV HA-ERK5wt (wild type) or empty 
plasmid (pCMV) using Superfect reagent (Qiagen), according to manufacturer’s 
recommendation. After 24 h, cells were serum starved and left for another 16-24 h before 
luciferase activities were determined using an automated optical plate reader (Dynatech 
MR 5000). For all transfections, cells were co-transfected with a β-gal-CMV plasmid to 
allow normalization of transfections. A total of 450ng DNA was transfected, which 
contained 300ng ERK5wt DNA, 100ng MMP-luc and 50ng β-galactosidase reporter.  
Western blotting  
Cultured cells were lysed directly on plates with 6 x SDS sample buffer containing 10% 
β-mercaptoethanol. Samples were denatured and analysed by SDS-PAGE, followed by 
transfer to nitrocellulose. Antibodies were used at the following dilutions: anti-ERK5, 
1:1000; and anti-α tubulin, 1:2000 (Santa Cruz, USA). Horse-radish peroxidase-
conjugated secondary antibodies (DAKO, High Wycombe, U.K.) were applied at 1:500  
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dilution and detected using enhanced chemiluminescence detection kit (ECL, Amersham).  
WST1 proliferation assay  
WST1 assays were carried out according to the manufacturer’s instructions (Roche, UK). 
PC3 cells were cultured in 96-well, flat-bottom tissue culture plates at a density of 5,000 
cells/well in a final volume of 100µl/well culture medium at 37°C, 5% CO
2
. After 48h, 
WST-1 reagent was added at a volume of 10µl/well and the cells incubated for up to 3 h. 
Absorbance at 450nm was measured using a microplate reader (Bio-Rad Laboratories 
Ltd., Model 680). Each assay was conducted in sets of ten and the experiment was 
repeated three times. Control wells containing culture medium and WST-1 reagent but no 
cells were also included in order to determine background fluorescence.  
Statistical analysis  
The statistical significance of trends between ERK5 expression and standard prognostic 
variables was assessed using the Mann-Whitney U and Kruskal-Wallis tests (Table 1) 
Linear regression analysis was employed to evaluate correlation of ERK5 and MEK5 
expression. Correlation of ERK5 expression and patient survival was analysed using the 
Kaplan-Meier method with log rank testing. Multivariate analysis was performed using 
the Cox regression model for survival data. Wilcoxon matched pairs test was used for 
matched tumour samples. All these tests were undertaken using SPSS, version 11.0, 
computer software (SPSS, Inc). A p-value of <0.05 was taken to indicate statistical 
significance.  
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Results  
ERK5 protein expression in resected human prostate cancer  
Normal and hyperplastic glands in the BPH group demonstrated either negative (n=2) or 
weak cytoplasmic staining (n=18). Analysis of staining patterns of ERK5 showed that, in 
the benign gland, expression was mainly localized to the glandular epithelium with 
patchy areas of weak stromal immunoreactivity (Figure 1A). Within the benign 
epithelium, weak ERK5 cytoplasmic immunoreactivity was seen in 18/20 cases. In 
contrast, when compared with BPH, cytoplasmic ERK5 expression was significantly 
upregulated in the malignant epithelium (Mann-Whitney U-test p<0.0001) (Figure 1B, 
1C). Increasing ERK5 expression is associated with less differentiated tumours: (1) The 
Kruskal-Wallis test demonstrated a significant association of ERK5 cytoplasmic 
immunoreactivity with Gleason sum score (p<0.0001) (Figure 2A); (2) Linear regression 
analysis revealed a strong significant correlation between ERK5 cytoplasmic protein 
expression and increasing Gleason sum score (p<0.0001; ρ=0.998). We then compared 
ERK5 cytoplasmic expression with our previous data on MEK5 cytoplasmic expression 
(matched cases, n=75)[17]. Linear regression demonstrated a strong significant 
correlation between ERK5 and MEK5 cytoplasmic expression (two sided p=0.0053; 
ρ=0.91) (Figure 2B). There was also a significant correlation between ERK5 cytoplasmic 
expression and the presence of bone metastases (p=0.0044) and extra-capsular (locally 
advanced) disease (p=0.0023). In our clinical series, with median follow-up of 42 months 
(range 0.5-126), increasing cytoplasmic ERK5 immunoreactivity was  
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significantly associated with an overall poor patient prognosis, comparing low and 
intermediate expression groups with the high expression group (p=0.036, Kaplan-Meier 
and log rank analysis) (Figure 2C). Further statistical analysis revealed that ERK5 
cytoplasmic expression did not relate to prostate-specific antigen levels (p=0.295).  
ERK5 nuclear staining is an independent prognostic marker in prostate cancer.  
Of particular interest, strong nuclear ERK5 signals was noted in 15 of the 81 PC cases 
(Figure 1D). This was in direct contrast to absent or scanty nuclear staining in the other 
66 cases of CaP and BPH controls (n=20). The presence of nuclear ERK5 over-
expression is strongly associated with poor patient prognosis (p<0.0001, Kaplan-Meier 
and log rank analysis) (Figure 2D). Further stratification revealed that strong nuclear 
expression retains its significant association with poorer patient prognosis, irrespective of 
Gleason grade (p=0.0008, Kaplan-Meier and log rank analysis) (Figure 2E) or presence of 
strong ERK5 cytoplasmic intensity (p=0.0052, Kaplan-Meier and log rank analysis) 
(Figure 2F). Multivariate analysis was carried out using Cox regression for survival data. 
For ERK5 cytoplasmic expression, this did not provide any further independent 
prognostic information, while ERK5 nuclear expression was shown to be an independent 
prognostic marker in prostate cancer (p<0.0001).  
ERK5 is more strongly expressed in androgen independent prostate cancer  
Analysis of ERK5 expression in matched tumour pairs revealed that the presence of 
ERK5 nuclear expression is significantly associated with the transition from hormone 
sensitive to hormone insensitive disease (p=0.0078) (Figure 1E, 1F). Non-significant  
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trends are seen with stronger ERK5 cytoplasmic expression in hormone relapsed disease 
(p=0.064). This was further investigated by performing western blot analysis for ERK5 
protein expression on lysates from the androgen dependent prostate cancer cell line, 
LNCaP, and its androgen independent derivative, LNCaP-DCC. The androgen 
independent LNCaP-DCC cells have increased ERK5 protein expression compared to the 
parental cells (Figure 3A).  
Localisation of ERK5 expression in human prostate cancer  
To evaluate localisation of ERK5 expression in human prostate cancer cell lines we 
transfected PC3 cells grown on a coverslip with EGFP-C1 ERK5 +/- pcMEK5D and 
viewed the cells under fluorescent light. Transfection with the GFP-ERK5 fusion protein 
alone resulted in strong cytoplasmic or perinuclear fluorescence, though ERK5 appeared 
to be excluded from the nucleus. However, co-transfection of the GFP-ERK5 expression 
vector with the pcMEK5D expression vector resulted in appearance of ERK5 in the 
nucleus with absence of cytoplasmic signalling. Both controls showed pan-cellular 
fluorescence (Figure 3B).  
ERK5 enhances MMP-1, MMP-2 and MMP-9 expression  
We identified a significant correlation between ERK5 overexpression and the presence of 
bony metastases in our clinical series (Figure 3C). We hypothesise that ERK5 may act as 
a modulator of genes involved in metastasis. The matrix metalloproteins (MMPs) 
constitute a broad family of zinc-binding endopeptidases that play a key role in the 
degradation of the extracellular matrix and basement membrane. To determine if ERK5  
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overexpression may modulate MMP expression, we transiently transfected ERK5 wild 
type DNA into PC3 cells and subsequent reporter gene assays were carried out with three 
separate MMP/Luciferase constructs (MMP-1, MMP-2 and MMP-9), corrected for β-
galactosidase, and empty vector as control. Upon ERK5 wild type transfection, MMP-1 
was found to have an approximate 4x fold induction relative to empty vector control. 
MMP-2 was found to be induced approximately 5.5x relative to control. MMP-9 was 
induced 4x relative to control. All three inductions were found to be statistically different 
to the empty vector control, (p value <0.001) (Figure 3D).  
Overexpression of ERK5 increases while inhibition of ERK5 activation suppresses 
proliferation in prostate cancer cells  
To test if proliferation is driven by overexpression of ERK5 in human prostate cancer, 
WST-1 assays were performed on PC3 cells overexpressing ERK5 (PC3-ERK5 cells). 
The proliferative index of ERK5 overexpressing cells was 2.7 fold greater than that of 
PC3 cells stably transfected with the vector alone (P<0.0001) (Figure 4A). Pre-incubation 
of the EcR293 MEK5D stable clone with the small molecule inhibitor PD184352 prior to 
PonA induction lead to inhibition of activation of ERK1/2 and ERK5. However, whereas 
1-3µм was sufficient to block the classical MAPK cascade, as judged by suppression of 
phosphorylation of ERK1/2, it was necessary to increase PD184352 to 10µм to suppress 
ERK5 activation (Figure 4B). A similar result was seen in PC3 cells where 0.3µм 
PD184352 was sufficient to block ERK1/2 activation and 3µм PD184352 was required to 
supress ERK5 activity (data not shown). Further proliferation analyses were performed in 
untransfected PC3 cells, pre-incubated at low dose 0.3µм PD184352,  
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sufficient to block ERK1/2 activation, and high dose 3µм PD184352 required to block 
ERK1/2 and ERK5 activation. Blockade of activation of the classic MAPK pathway was 
found to cause an increase in cellular proliferation, but this increase did not quite reach 
statistical significance (P=0.0728). However, pre-incubation at the higher dose of the 
inhibitor caused a statistical decrease in proliferation (P<0.0001) (Figure 4C).  
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Discussion  
In keeping with our previous findings on MEK5, here we report our original findings of 
ERK5 overexpression in resected human prostate cancer. Importantly, we demonstrated a 
strong, linear correlation between MEK5 and ERK5 protein expression in matched cases 
(P=0.0053). This close relationship ties in with current knowledge of ERK5 as the only 
known substrate of MEK5, and phosphorylated MEK5 as the only known activating 
molecule of ERK5 [2, 23]. We have demonstrated a significant correlation between 
ERK5 cytoplasmic overexpression and Gleason sum score (P<0.0001); the inference 
being that the higher the Gleason grade of the disease, the higher the ERK5 protein 
expression in the tumour cells. This correlation was not observed between MEK5 
overexpression and Gleason sum score [17]. In keeping with the notion that ERK5 has a 
more important role in carcinogenesis, a previous report studying the in vitro 
phosphorylation and activation status of ERK5 revealed evidence for ERK5 auto-
phosphorylation, as well as its ability to phosphorylate MEK5 extensively at residues 129, 
137, 142 and 149 [23]. Taken together, these results suggest that ERK5 is the driving 
molecule in this pathway and perhaps, not surprisingly, has a closer correlation with 
clinical parameters than MEK5.  
We also discovered a significant correlation between ERK5 cytoplasmic expression and 
the presence of bone metastases (p=0.002). The clinical picture in the advanced stages of 
prostate cancer is dominated by the problem of bony metastases, which occur in 
approximately 90% of patients, representing the most important cause of morbidity, 
causing bone pain and complications such as pathological fracture, immobility,  
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haemopoietic compromises and spinal cord compression [24, 25]. A number of cytokines 
have been implicated in bony metastasis, including BMP-6 [26], TGFβ1 [27], interleukin 
6 (IL-6) and IL-6 receptor [28, 29]. It is therefore of interest that a recent paper has 
identified IL-6 as an activator of ERK5 in multiple myeloma cells [30].  
In normal prostate development, the interaction of prostate epithelial cells with 
surrounding stroma influences their growth, survival and differential potential. 
Components of the surrounding stroma include numerous cell types, such as fibroblast, 
endothelial, neuroendocrine and inflammatory cells, soluble growth factors and insoluble 
laminin-rich extracellular matrix (ECM). Many of the steps in cancer metastasis involve 
the production of ECM degrading proteases and compromised cell adhesion [31]. The 
matrix metalloproteinases (MMPs) are a key family of zinc-dependent enzymes involved 
in metastatic development that are known to be regulated by MAPK family members. 
MMPs play an important role in ECM remodelling, and a positive correlation between 
MMP expression and tumour progression has been demonstrated in both human and 
animal studies [32]. We have previously observed that activation of MEK5 results in the 
upregulation of MMP-9 transcription, demonstrating a moderate increase in promoter 
activity and confirming this induction at the mRNA level. Consistent with this here we 
have found that MMP family members -1, -2 and -9 are upregulated following ERK5 
activation. Better understanding of the mechanisms involved in the formation of 
metastatic bony lesions in prostate cancer will facilitate the development of new 
therapeutic agents.  
In addition, this study shows that increased cytoplasmic ERK5 expression correlates with 
a less favourable disease-specific survival, comparing low and intermediate expression  
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groups with the high expression group (P=0.036, Kaplan-Meier and log rank analysis). 
This result is in accord with that seen previously with MEK5 expression and survival [17]. 
Another important finding is revealed in the second immunohistochemical analysis, 
examining ERK5 expression in matched tumour pairs, revealing that the presence of 
ERK5 nuclear expression is significantly associated with the transition from hormone 
sensitive to hormone insensitive disease (P=0.0078). Non-significant trends are seen with 
stronger ERK5 cytoplasmic expression in hormone relapsed disease (P=0.064). Further 
evidence of increased ERK5 expression in androgen independent disease is evident from 
western blot analysis comparing androgen dependent LNCaP cells, and its androgen 
independent derivative LNCaP-DCC cells. The androgen independent derived cells, 
LNCaP-DCC, have increased ERK5 protein expression.  
Of great interest in this paper is the finding that the presence of strong nuclear ERK5 
expression was shown to have a strong significant association with poorer patient 
prognosis (P<0.0001). The strong nuclear expression retains this significant association 
with survival, irrespective of Gleason grade (P=0.0008) or presence of strong ERK5 
cytoplasmic intensity (P=0.0052). A major novel finding of this paper is that a 
multivariate analysis, by Cox regression, demonstrated that ERK5 nuclear expression is 
an independent prognostic marker in prostate cancer (P<0.0001). In light of this, it is also 
interesting to note that in this paper we find that co-transfection of an ERK5 wild type 
with a MEK5D expression plasmid lead to nuclear accumulation of ERK5 in the prostate 
cancer cell line, PC3. This has previously been observed in CHO-K1 cells [7]. The 
duration and magnitude of MAPK activation on one hand, and the localization of MAPKs 
on the other hand have been identified as critical parameters that define specific  
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cellular responses [33, 34]. Nucleo-cytoplasmic transport of signalling molecules is 
essential for the regulation of eukaryotic cellular processes such as cell cycle progression, 
differentiation and circadian clocks [35, 36]. In the context of MAPK signalling, 
relocalisation of MAPKs from the cytosol to the nucleus is essential for phosphorylating 
and activating those transcription factors within the nuclear compartment [34, 37]. 
Buschbeck and Ullrich (2005) have analysed several cell lines and shown that, 
unsurprisingly, endogenous ERK5 is localised to cytoplasmic as well as nuclear 
compartments. They proposed a simplified model of ERK5 in which we can consider 
ERK5 to exist in a closed or open conformation. Under steady-state conditions, and in the 
absence of any factor, the majority of ERK5 is assumed to adopt the closed formation, 
under which ERK5 activation by MEK5 is hampered resulting in a dominant cytosolic 
localisation. The open conformation, on the other hand, facilitates activation and leads to 
nuclear accumulation [38].  
In this study we have identified a subgroup of patients with strong nuclear ERK5 
expression and very poor survival. These observations, including those of Buschbeck and 
Ullrich (2005), lead us to believe that, in this subgroup, the ability of the cell to 
dephosphorylate or shuttle activated ERK5 out of the nucleus has been lost, leading to 
increased transcription and, in turn, more aggressive disease culminating in decreased 
survival. The exact mechanism of how this abnormal, unsteady state arises is of great 
interest both biochemically and clinically as we have demonstrated that ERK5 nuclear 
expression is an independent prognostic factor in prostate cancer and, in tandem with 
PSA, may have a future in predicting disease prognosis.  
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Another possible mechanism explaining the increased nuclear expression of ERK5 stems 
from the recently published study establishing that in the mouse fibroblast cell line, 
NIH3T3, treatment with 1µM PD184352 (a MEK1/2 inhibitor) enhances nuclear 
accumulation of ERK5, suggesting that when ERK1/2 is suppressed, ERK5 activation is 
enhanced [39]. This is of interest in the light of the observations of Uzgare et al. (2003), 
who established that activation of ERK1/2 occurs in the early progression of prostate 
cancer but subsequent inactivation of ERK1/2 is contemporaneous with the emergence of 
the poorly differentiated, metastatic phenotype. Evidence for cross-talk between the 
ERK1/2 pathway and ERK5 has previously been suggested by the observation of Mody 
and co-workers [19], in that 1µM PD184352 led to a more sustained activation of ERK5 
following growth factor stimulation. Our proliferation assays revealed firstly that ERK5 
overexpression in human prostate cancer leads to increased proliferation, and secondly 
that pre-incubation of prostate cells with low dose PD184352, sufficient to block ERK1/2 
activation, does not cause a decrease in cell proliferation; in fact cell proliferation is 
actually increased, though not quite significantly (P=0.0728), in these experiments. 
PD184352 (CI-1040) showed promise in a phase I trial of 77 heavily pre-treated patients 
achieving 28% stable disease in this population, but no objective responses were noted in 
a Phase II setting tested against various solid neoplasms [40, 41]. We now know 
PD184352 also blocks ERK5 activation and it is not clear, as it was not considered, if the 
given dose was high enough to block ERK5 activation in these studies.  
In this paper, we have discovered a close association between ERK5 expression and 
adverse clinical parameters in human prostate cancer. The finding of strong nuclear 
ERK5 staining and its strong correlation with less favourable disease survival, and  
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androgen independent disease, opens up another field in the elucidation of our 
understanding of the role of the MEK5/ERK5 pathway in prostate cancer. Further studies 
are required to clarify the mechanism and consequences of ERK5 nuclear localisation. Of 
clinical importance, ERK5 nuclear staining has here been shown to be an independent 
marker of prognosis in prostate cancer, and may prove useful as a stratification tool to 
identify a more aggressive/ metastatic phenotype.  
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